From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

By Rose McNulty

July 31st 2025

Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).

Gene therapy appears to be a promising approach for a subset of genetic deafness. | Image credit: NathanDeverycom - stock.adobe.com

Progress and Challenges With Gene Therapy in Hereditary Hearing Loss

By Rose McNulty

July 31st 2025

Gene therapy appears to be a promising approach for a subset of genetic deafness, although challenges remain with development and manufacturing.

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com

Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

By Maggie L. Shaw

July 31st 2025

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.

...

112 113 114 115 116

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions